NewLink Genetics (NLNK) Price Target Lowered to $18.00 at Bank of America
Several other equities research analysts have also recently weighed in on NLNK. Cantor Fitzgerald reissued a buy rating and set a $26.00 price objective on shares of NewLink Genetics in a research note on Thursday, November 2nd. Stifel Nicolaus boosted their price objective on NewLink Genetics from $25.00 to $29.00 and gave the stock a buy rating in a research note on Friday, November 3rd. Jefferies Group reduced their price objective on NewLink Genetics from $26.00 to $25.00 and set a buy rating on the stock in a research note on Friday, November 3rd. Zacks Investment Research raised NewLink Genetics from a hold rating to a buy rating and set a $10.00 price objective on the stock in a research note on Tuesday, November 7th. Finally, BidaskClub raised NewLink Genetics from a sell rating to a hold rating in a research note on Friday, January 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock has an average rating of Buy and an average target price of $21.57.
Shares of NewLink Genetics (NASDAQ NLNK) opened at $7.59 on Friday. NewLink Genetics has a 52 week low of $5.90 and a 52 week high of $25.17.
TRADEMARK VIOLATION NOTICE: “NewLink Genetics (NLNK) Price Target Lowered to $18.00 at Bank of America” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/05/newlink-genetics-nlnk-price-target-lowered-to-18-00-at-bank-of-america.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.